NOT-AI-22-005: Notice of Early Expiration of PAR-19-078, Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)"

Notice of Early Expiration of PAR-19-078, “Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)"

Notice Number:

NOT-AI-22-005

Key Dates

Release Date:

November 29, 2021

Related Announcements

PAR-19-078 - Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)

NOT-AI-21-082 - Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to inform the extramural community of the early expiration of PAR-19-078 - Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed), effective immediately. The Key Dates section of the FOA has been modified to change the Expiration Date from January 8, 2022 to November 29, 2021.

Applicants are encouraged to consider applying to NOT-AI-21-082, “Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity”.

Inquiries

Please direct all inquiries to:

Frosso Voulgaropoulou, PhD
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3205
Email: fvoulgaropoulou@niaid.nih.gov